Throughout the year, our teams enhanced patient care through evidence-based practice and robust clinical governance, led by the Quality and Medication Safety Unit (QMSU). These efforts delivered consistent, high-quality pharmacy services across metropolitan and regional settings, including the successful completion of QCPP reaccreditation at 10 sites. Our teams also supported more than 7,400 patient visits through clinical trial medication services, while individual excellence was recognised with Margaret Patterson named Best First-Time Poster Presenter at MM25.
A year of impact across Slade Pharmacy
As 2025 draws to a close, Slade Pharmacy proudly reflects on a year of progress across our national network, driven by clinical excellence, education, research, and strong governance.
Professional development remained a key priority in 2025, with 24 interns supported through the pharmacy internship program and eight pharmacists participating in the AdPha Resident Training Program. Our commitment to research and professional leadership was further demonstrated through 10 research posters and two oral presentations delivered at national pharmacy conferences, alongside 22 national education presentations presented by 20 team members.
We strengthened collaboration and knowledge sharing across the network by launching two new clinical interest groups in mental health and cardiology, and introducing two new foundation specialty practice certificate courses in critical care and mental health.
These achievements reflect our ongoing commitment to delivering safe, high-quality, and continuously improving pharmacy services. We thank our teams and hospital partners for another year of collaboration and shared purpose, and we look forward to continuing this momentum in the year ahead.
